Respiratory Inhalers – our new study reveals trends, R&D progress, and predicted revenues
Where is the Respiratory Inhalers market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.
Discover how to stay ahead
Our 181-page report provides 118 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Respiratory Inhalers market. See how to exploit the opportunities.
Forecasts to 2027 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, 8 Products and 3 indications are also forecasted.
Respiratory Inhalers Market Forecasts to 2027, by Product:
• Metered Dose Inhalers
• Dry Powder Inhalers
– Single-Dose DPIs
– Multi-Dose DPIs
• Nebulizers
– Jet / Compressor Nebulizers
– Ultrasonic Nebulizers
– Vibrating-Mesh Nebulizers
Respiratory Inhalers Market Forecasts to 2027, by Application:
• Asthma
• COPD
• Other Respiratory Diseases
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 12 leading national markets:
• The US
• The EU5 markets
– Germany
– France
– UK
– Italy
– Spain
• Japan
• China
• India
• Russia
• Brazil
• Mexico
The report also includes profiles and forecasts for some of the leading companies in the Respiratory Inhalers device market, with a focus on the Respiratory Inhalers device segment of these companies’ operations.
There will be growth in both established and in developing countries. Our analyses show that the developing markets, China and India in particular, will continue to achieve high revenue growth to 2027. Developments worldwide in medical device regulation, especially in the US and Japan will influence the market.
Leading companies and the potential for market growth
Overall world revenue for Respiratory Inhalers will surpass $33.2bn in 2017, our work calculates. We predict strong revenue growth through to 2027. The increasing use of Respiratory Inhalers across many types of surgery and increasing ageing population will increase sales to 2027.
Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Respiratory Inhalers Market report helps you
In summary, our 181-page report provides you with the following knowledge:
• Revenue forecasts to 2027 for the world Respiratory Inhalers market and 2 different segmentations, with 8 product types and 3 applications – discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2027 for 12 of the leading national markets – US, Mexico, Brazil, Germany, UK, France, Italy, Spain, Japan, China, India, the Rest of World markets.
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the Respiratory Inhalers device market and leading companies. You find data, trends and predictions.
Get our report today The Global Respiratory Inhalers Market 2017-2027: Revenue Prospects by Product Type (Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers), by Indication (Asthma and COPD) and Geography. Avoid missing out – get our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Global Respiratory Inhalers Market Overview
1.2 Global Respiratory Inhalers Market Segmentation
1.3 Overview of Findings
1.4 Structure of the Report
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8 Who is This Report For?
1.9 Methodology
1.9.1 Primary Research
1.9.2 Secondary Research
1.9.3 Market Evaluation & Forecasting Methodology
1.10 Frequently Asked Questions (FAQ)
1.11 Associated Visiongain Reports
1.12 About Visiongain
2. Introduction to Respiratory Disorders and Therapies
2.1 An Introduction to Respiratory Disorders
2.1.1 Classification of Respiratory Disorders
2.1.2 Asthma
2.1.2.1 Trends in Asthma Prevalence
2.1.2.2 Pathophysiology of Asthma
2.1.2.3 Symptoms of Asthma
2.1.2.4 Treatment of Asthma
2.1.2.5 Guidelines for Asthma Treatment
2.1.2.6 Drug Treatments for Asthma
2.1.3 Chronic Obstructive Pulmonary Disease (COPD)
2.1.3.1 Trends in COPD Prevalence
2.1.3.2 Pathophysiology of COPD
2.1.3.3 Symptoms of COPD
2.1.3.4 Treatment of COPD
2.1.3.5 Drug Treatments for COPD
2.1.3.6 Guidelines for COPD Treatment
2.2 Major Drug Classes in the Treatment of Asthma and COPD
2.2.1 Bronchodilators
2.2.1.1 Beta2-Agonists
2.2.1.2 Anticholinergics
2.2.1.3 Anti-Inflammatory Drugs
2.2.1.4 Corticosteroids
2.2.1.5 Leukotriene Receptor Antagonists
2.2.1.6 Monoclonal Antibodies in the Treatment of Respiratory Disease
2.2.1.7 Combination Drugs
2.2.2 Phases of Clinical Trials
2.2.3 Regulation of Medical Devices
2.2.3.1 The US Approval and Regulation System
2.2.3.2 The EU Approval and Regulation System
2.2.3.3 Post-Marketing Surveillance in the EU
3. Respiratory Inhalers: Global Market 2016-2027
3.1 The Global Respiratory Inhalers Market in 2016
3.2 Leading Respiratory Inhaler Products
3.3 Leading Companies in the Respiratory Inhalers Market
3.4 Respiratory Inhalers: Trends and Developments
3.4.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers
3.4.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?
3.4.3 Telehealth: A Promising Market Trend
3.4.4 Lifecycle Management Strategies to Counter Patent Expiry
3.4.5 Advanced Inhaler Technologies to Counter Generic Erosion
4. Respiratory Inhalers Market, By Product Type
4.1 Metered Dose Inhalers: Market Overview
4.2 Dry Powder Inhalers: Market Overview
4.2.1 Single-Dose DPIs
4.2.2 Multi-Dose DPIs
4.3 Nebulizers: Market Overview
4.3.1 Jet/Compressor Nebulizers
4.3.2 Ultrasonic Nebulizers
4.3.3 Vibrating-Mesh Nebulizers
5. Respiratory Inhalers Market, by Indication
5.1 Asthma: Market Overview
5.2 COPD: Market Overview
5.3 Other Respiratory Diseases
6. Leading National Markets 2016-2027
6.1 Regional Breakdown of the Global Respiratory Inhalers Market
6.2 World Respiratory Inhalers Market Forecast 2016-2027
6.2.1 How will Regional Market Shares Change to 2027?
6.3 The US Respiratory Inhalers Market 2016-2027
6.3.1 The US Respiratory Inhalers Market Forecast 2016-2027
6.3.2 US Respiratory Inhalers Market: Trends and Developments
6.4 EU5 Respiratory Inhalers Market 2016-2027
6.4.1 German Respiratory Inhalers Market Forecast 2016-2027
6.4.2 French Respiratory Inhalers Market Forecast 2016-2027
6.4.3 UK Respiratory Inhalers Market Forecast 2017-2027
6.4.4 Italian Respiratory Inhalers Market Forecast 2017-2027
6.4.5 Spanish Respiratory Inhalers Market Forecast 2017-2027
6.4.6 EU5 Respiratory Inhalers Market: Trends and Developments
6.4.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law
6.4.6.2 France: Social Security Finance Bill 2015
6.4.6.3 UK: Improving Asthma and COPD Patient Outcomes
6.4.6.4 Italy: Austerity Measures Limiting Growth
6.4.6.5 Spain: The Start of Recovery in the Spanish Economy
6.5 Japanese Respiratory Inhalers Market 2016-2027
6.6 BRIC Respiratory Inhalers Market 2016-2027
6.6.1 Chinese Respiratory Inhalers Market Forecast 2016-2027
6.6.2 Indian Respiratory Inhalers Market Forecast 2016-2027
6.6.3 Brazilian Respiratory Inhalers Market Forecast 2016-2027
6.6.4 Russian Respiratory Inhalers Market Forecast 2016-2027
6.7 Mexican Respiratory Inhalers Market Forecast 2016-2027
7. Leading Companies in the Respiratory Inhalers Market
7.1 GlaxoSmithKline (GSK)
7.1.1 GSK: Product Portfolio
7.1.2 GSK: Financial Overview
7.1.3 Recent Developments
7.1.3.1 Japanese Regulatory Approval for Relvar Ellipta
7.1.3.2 FDA Filing of Triple Drug Therapy
7.1.3.3 FDA Approval for Breo Ellipta to Adult Asthma Patients
7.1.3.4 Launch of Combination Drugs
7.1.3.5 GSK Presented Data on Eosinophil Levels and COPD
7.1.3.6 Approval for Arnuity Ellipta
7.1.3.7 Approval for Incruse Ellipta
7.1.3.8 GSK: Products in Development
7.2 AstraZeneca
7.2.1 AstraZeneca: Product Portfolio
7.2.2 AstraZeneca: Financial Overview
7.2.3 Recent Developments
7.2.3.1 FDA Approval for Symbicort in Paediatric Patients
7.2.3.2 Charity-Industry Collaboration
7.2.3.3 FDA approval for Bevespi Aerosphere
7.2.3.4 AstraZeneca Acquired Right to Actavis’ Branded Respiratory Portfolio in US and Canada
7.2.3.5 AstraZeneca Acquired Almirall’s Respiratory Portfolio
7.2.3.6 Takeda Respiratory Portfolio Acquisition
7.2.4 AstraZeneca: Products in Development
7.3 Boehringer Ingelheim
7.3.1 Boehringer Ingelheim: Product Portfolio
7.3.2 Boehringer Ingelheim: Financial Overview
7.3.3 Recent Developments
7.3.3.1 Collaboration with Kaohsiung Medical University
7.3.3.2 Collaboration with Weill Cornell Medicine
7.3.3.3 Collaboration with Qualcomm Incorporated
7.3.3.4 Partnership with Propeller Health
7.3.3.5 FDA Approval for Spiriva Respimat
7.3.3.6 Regulatory Approval for Stiolto Respimat
7.3.3.7 Expansion of Respimat Manufacturing Capacity
7.3.3.8 FDA Approval for Stiverdi Respimat
7.3.4 Boehringer Ingelheim: Respiratory Product Pipeline
7.4 Merck & Co. (Merck)
7.4.1 Merck: Product Portfolio
7.4.2 Merck: Financial Overview
7.4.3 Recent Developments
7.4.4 Merck: Products in Development
7.5 Teva
7.5.1 Teva: Product Portfolio
7.5.2 Teva: Financial Overview
7.5.3 Teva: Recent Developments
7.5.3.1 FDA Approval for RespiClick
7.5.3.2 European Approval for Aerivio Spiromax
7.5.3.3 FDA Approval for ProAir RespiClick (albuterol sulfate)
7.5.3.4 Acquisition of Gecko Health Innovations
7.5.3.5 Partnership with IBM Watson Health
7.5.4 Teva: Products in Development
7.6 Novartis International AG
7.6.1 Novartis: Product Portfolio
7.6.2 Novartis: Financial Overview
7.6.3 Novartis: Recent Developments
7.6.3.1 Partnership with Propeller Health
7.6.3.2 Exclusive License Agreement with Sunovion Pharma
7.6.3.3 Partnership with Qualcomm Incorporated
7.6.3.4 FDA Approval for Utibron Neohaler
7.6.3.5 Novartis Presented Data on Ultibro and Seebri
7.6.3.6 Pfizer Promotes Two Novartis COPD drugs in the UK
7.6.4 Novartis: Products Under Development
7.7 Chiesi Farmaceutici S.p.A.
7.7.1 Chiesi: Product Portfolio
7.7.2 Chiesi: Financial Overview
7.7.3 Chiesi: Recent Developments
7.7.3.1 Regulatory Approval for NEXThaler
7.7.3.2 Chiesi: Products Under Development
8. Qualitative Analysis of Respiratory Inhalers Market
8.1 Market Dynamics
8.1.1 Drivers and Opportunities
8.1.1.1 Growing Burden of Respiratory Diseases
8.1.1.2 Smart Inhalers Provide High Growth Opportunities
8.1.1.3 Triple Drug Therapy for COPD To Offer New Revenue Prospects
8.1.2 Restraints and Challenges
8.1.2.1 Patent Expiry and Generic Competition
8.1.2.2 High Cost Impeding Growth of DPIs In Cost-Sensitive Markets
8.2 Porter’s Five Forces Analysis of the Respiratory Inhalers Market
8.2.1 Rivalry among Competitors [Medium]
8.2.2 Threat of New Entrants [Medium]
8.2.3 Power of Suppliers [Medium]
8.2.4 Power of Buyers [High]
8.2.5 Threat of Substitutes [Low]
9. Conclusions
9.1 Respiratory Inhalers: A Maturing Market
9.2 The Global Respiratory Inhalers Market, 2016 - 2027
9.3 Leading Respiratory Inhalers
9.4 Leading Respiratory Inhaler Companies
9.5 Leading Regional and National Markets
9.6 Global Respiratory Inhalers Market Forecast, 2017-2027
9.7 The Future of Respiratory Inhalers Market
10. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
List of Figures
Figure 1.1 Ageing Population Estimates 2010 - 2050
Figure 1.2: Global Respiratory Inhalers: Market Segmentation
Figure 2.1 Summary of GINA Guidance for Asthma Treatment, 2016
Figure 2.2 Summary of GOLD Guidance for COPD Treatment
Figure 3.1 World Respiratory Inhalers Market: Market Shares (%) for Major National Markets
Figure 3.2 Top 5 Respiratory Inhalers: Market Shares (%), 2016
Figure 4.1 Respiratory Inhalers Market Forecast: Revenues ($m) by Product Type, 2016-2027
Figure 4.2 Metered Dose Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 4.3 World Dry Powder Inhalers Market Forecast: Revenues ($m) by Product Type, 2016-2027
Figure 4.4 Single-dose DPI Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 4.5 Multi-dose DPI Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 4.6 Jet Nebulisers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 4.7 Ultrasonic Nebulisers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 4.8 Vibrating-mesh Nebulisers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 5.1 World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), By Disease Indication, 2016-2027
Figure 5.2 World Asthma Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 5.3 World COPD Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 5.4 World Other Respiratory Diseases Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.1 Respiratory Inhalers Market: Revenues ($m) by Region, 2016
Figure 6.2 World Respiratory Inhalers Market: Market Shares (%) by Region, 2016
Figure 6.3 World Respiratory Inhalers Market Forecast: Revenues ($m) by Region, 2016-2027
Figure 6.4 World Respiratory Inhalers Market: Market Shares (%) by Region, 2016
Figure 6.5 World Respiratory Inhalers Market: Market Shares (%) by Region, 2022
Figure 6.6 World Respiratory Inhalers Market: Market Shares (%) by Region, 2027
Figure 6.7 US Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.8 EU5 Respiratory Inhalers Market Forecast: Revenues ($m) by National Market, 2016-2027
Figure 6.9 German Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.10 French Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.11 UK Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%), 2016-2027
Figure 6.12 Italian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.13 Spanish Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.14 Japanese Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.15 BRIC Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.16 Chinese Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.17 Indian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.18 Brazilian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.19 Russian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 6.20 Mexican Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 7.1 GSK: Major Respiratory Inhalers Revenue ($m), 2016
Figure 7.2 GSK: Major Respiratory Inhalers Revenue Share (%), by Product, 2016
Figure 7.3 GSK: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027
Figure 7.4 AstraZeneca: Major Respiratory Inhalers Revenue ($m), 2016
Figure 7.5 AstraZeneca: Major Respiratory Inhalers Revenue Share (%), by Product, 2016
Figure 7.6 AstraZeneca: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027
Figure 7.7 Boehringer Ingelheim: Major Respiratory Inhalers Revenue ($m), 2016
Figure 7.8 Boehringer Ingelheim: Major Respiratory Inhalers Revenue Share (%), by Product, 2016
Figure 7.9 Boehringer Ingelheim: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027
Figure 7.10 Merck: Major Respiratory Inhalers Revenue ($m), 2016
Figure 7.11 Merck: Major Respiratory Inhalers Revenue Share (%), by Product, 2016
Figure 7.12 Merck: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027
Figure 7.13 Teva: Major Respiratory Inhalers Revenue ($m), 2016
Figure 7.14 Teva: Major Respiratory Inhalers Revenue Share (%), by Product, 2016
Figure 7.15 Teva: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027
Figure 7.16 Novartis: Major Respiratory Inhalers Revenue ($m), 2016
Figure 7.17 Novartis: Major Respiratory Inhalers Revenue Share (%), by Product, 2016
Figure 7.18 Novartis: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027
Figure 7.19 Chiesi: Foster Inhaler Revenue ($m) and AGR (%), 2016-2027
Figure 8.1 Porter’s Five Forces Analysis of the Respiratory Inhalers Market, 2016-2027
Figure 9.1 Respiratory Inhalers Market Forecast: Revenues ($m) by Product Type, 2016-2027
List of Tables
Table 1.1 Respiratory Inhalers Market Forecast Segmented by National Markets: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 2.1 Classification of Respiratory Diseases
Table 2.2 Clinical Trial Phases
Table 3.1 Top 5 Respiratory Inhalers: Revenue ($m) and Market Shares (%), 2016
Table 4.1 World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), By Product Type, 2016-2027
Table 4.2 World Metered Dose Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.3 World Dry Powder Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Product Type, 2016-2027
Table 4.4 Types of Marketed Breezhaler Device
Table 4.5 Single-dose DPI Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.6 Multi-dose DPI Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.7 World Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Type, 2016-2027
Table 4.8 World Jet Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.9 World Ultrasonic Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.10 World Vibrating-mesh Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.1 World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), By Disease Indication, 2016-2027
Table 5.2 World Asthma Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.3 World COPD Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.4 World Other Diseases Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.1 World Respiratory Inhalers Market: Revenues ($m) and Market Shares (%) by Region, 2016
Table 6.2 World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Region, 2016-2027
Table 6.3 Market Shares (%) of Leading Regional Respiratory Inhalers Markets, 2016, 2022 and 2027
Table 6.4 US Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.5 EU5 Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2016-2027
Table 6.6 German Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.7 French Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.8 UK Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.9 Italian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.10 Spanish Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.11 Japanese Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.12 BRIC Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.13 Chinese Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.14 Indian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.15 Brazilian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.16 Russian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.17 Mexican Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.1 GSK: Overview, 2016
Table 7.2 GSK: Respiratory Inhaler Products
Table 7.3 GSK: Major Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%), By Product Type, 2016-2027
Table 7.4 GSK: Respiratory Therapies Pipeline, 2016
Table 7.5 AstraZeneca: Overview, 2016
Table 7.6 AstraZeneca: Respiratory Inhaler Products
Table 7.7 AstraZeneca: Major Respiratory Inhalers Revenue ($m), AGR (%) and CAGR (%), by Product Type, 2016-2027
Table 7.8 AstraZeneca: Respiratory Therapies Pipeline, 2016
Table 7.9 Boehringer Ingelheim: Overview, 2016
Table 7.10 Boehringer Ingelheim: Respiratory Inhaler Products
Table 7.11 Boehringer Ingelheim: Major Respiratory Inhalers Revenue ($m), AGR (%) and CAGR (%), by Product Type, 2016-2027
Table 7.12 Merck: Overview, 2016
Table 7.13 Merck: Respiratory Inhaler Products
Table 7.14 Merck: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2027
Table 7.15 Teva: Overview, 2016
Table 7.16 Teva: Respiratory Inhaler Products
Table 7.17 Teva: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2027
Table 7.18 Teva: Respiratory Product Pipeline, 2016
Table 7.19 Novartis: Overview, 2016
Table 7.20 Novartis: Respiratory Inhaler Products
Table 7.21 Novartis: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2027
Table 7.22 Novartis: Respiratory Product Pipeline, 2016
Table 7.23 Chiesi: Overview, 2016
Table 7.24 Chiesi: Respiratory Inhaler Products
Table 7.25 Chiesi: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2027
Table 9.1 Top 10 Respiratory Inhalers: Revenue ($m) and Market Shares (%), 2016
3M Drug Delivery Systems
Actavis
Adherium Limited
Aerogen
Agilent Technology
Airssential
Allied Healthcare
Almirall
Astrazeneca
Boehringer Ingelheim
Briggs Healthcare
CareFusion
Chiesi
Cipla
Clement Clarke International
Cohero Health
DeVilbiss Healthcare
Fexicare
Gecko Health Innovations
GF Health Products
GlaxoSmithKline
Heyer Medical
Hikma
Innovate Biomed
Inspiro Medical
Medline Surgical
Merck
MRK Healthcare
Mylan
Nexus 6
Nouvag AG
Novartis
Omron Healthcare
Opko Health
Orion Pharma
PARI Medical
Pfizer
Philips Respironics
Propeller Health
Qualcomm Incorporated
Roche
Schering-Plough
Sunovion Pharma
Takeda Pharmaceutical Company Limited
Teva Pharmaceuticals
Vectura
Viatris
Organizations/Associations Mentioned in the Report
British Lung Foundation
Centers for Disease Control and Prevention
Centre for Devices and Radiological Health
European Databank on Medical Devices
European Medicines Agency
European Respiratory Society
Food and Drug Administration
German Ministry of Health
Global Initiative for Asthma
Global Initiative for Chronic Obstructive Lung Disease
IBM Watson Health
Kaohsiung Medical University
Ministry of Health, Labour and Welfare
Mount Sinai Hospital
MRC Technology
ServicioSanitarioNazionale
UK NHS
US National Heart, Lung, and Blood Institute
US National Institutes of Health
Weill Cornell Medicine
World Health Organization (WHO)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
